Toronto Dominion Bank Invests $24.88 Million in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Toronto Dominion Bank bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 540,024 shares of the company’s stock, valued at approximately $24,879,000. Toronto Dominion Bank owned 1.93% of Establishment Labs as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Assenagon Asset Management S.A. bought a new stake in shares of Establishment Labs during the fourth quarter worth approximately $12,898,000. R Squared Ltd acquired a new stake in Establishment Labs during the 4th quarter worth approximately $36,000. Handelsbanken Fonder AB lifted its holdings in Establishment Labs by 32.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock worth $378,000 after purchasing an additional 2,000 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Establishment Labs in the 4th quarter valued at $5,494,000. Finally, Black Swift Group LLC grew its holdings in Establishment Labs by 98.6% in the 4th quarter. Black Swift Group LLC now owns 14,300 shares of the company’s stock valued at $659,000 after buying an additional 7,100 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Down 1.3%

ESTA opened at $36.16 on Monday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -14.02 and a beta of 0.73. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $58.00. The company has a 50-day simple moving average of $34.41 and a 200 day simple moving average of $38.18.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.13. The company had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) EPS. Analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ESTA shares. BTIG Research began coverage on shares of Establishment Labs in a research report on Friday. They issued a “buy” rating and a $62.00 target price for the company. Stephens reissued an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Finally, Needham & Company LLC raised shares of Establishment Labs from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $55.33.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.